Innate Pharma (IPHA) Current Deferred Revenue (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Current Deferred Revenue data on file, last reported at $3.3 million in Q4 2025.

• For the quarter ending Q4 2025, Current Deferred Revenue rose 399.57% year-over-year to $3.3 million; the trailing twelve-month figure through Dec 2025 stood at $3.3 million (up 399.57% YoY), and the FY2025 full-year result was $3.3 million, up 399.57% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $3.3 million, up from $637293.3 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $14.3 million in Q4 2021 and bottomed at $637293.3 in Q2 2025.
• The 5-year median for Current Deferred Revenue is $5.9 million (2023), against an average of $6.3 million.
• The widest annual swing landed in 2021, when Current Deferred Revenue slumped 99.97%; it then soared 399.57% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $14.3 million in 2021, then slumped by 53.2% to $6.7 million in 2022, then slipped by 5.71% to $6.3 million in 2023, then tumbled by 89.57% to $658254.8 in 2024, then jumped by 399.57% to $3.3 million in 2025.
• The last three Current Deferred Revenue figures came in at $3.3 million (Q4 2025), $637293.3 (Q2 2025), and $658254.8 (Q4 2024), per Business Quant data.

Peer Comparison